Immudyne, Inc. Announces Name Change & Rebranding to Conversion Labs, Inc.
NEW YORK, July 10, 2018 (GLOBE NEWSWIRE) -- Conversion Labs, Inc (formerly Immudyne, Inc.,) (the “Company” or “Conversion Labs”) is pleased to announce its formal name change to Conversion Labs, Inc. As part of the rebranding, the Company is now trading under the new ticker symbol “CVLB” and has launched a new website at www.conversionlabs.com.
Conversion Labs is a technology-driven e-commerce company that builds innovative and proprietary brands. The Company leverages the world’s largest social media, search and e-commerce platforms (Facebook, Google & Amazon) to rapidly and profitably grow a continually expanding product portfolio.
“We have seen the rise of e-commerce and believe that Conversion Labs is in a strong position to take advantage of shifts towards online marketing. The rebranding symbolizes our Company’s transformation to becoming a leader in online direct-response marketing,” stated Justin Schreiber, Conversion Labs’ President and CEO.
The Company’s common stock will continue to be listed on OTCQB. No action is needed from current shareholders in connection to the name and ticker symbol change.
About Conversion Labs
Conversion Labs is a technology-driven e-commerce company that builds innovative and proprietary brands. Conversion Labs’ scalable and global advertising technology infrastructure leverages the world’s largest social media, search and e-commerce platforms (Facebook, Google & Amazon) to rapidly and profitably grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.conversionlabs.com or email us at [email protected].
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, among other thing, statements regarding the offering, the expected gross proceeds, the expected use of proceeds and the expected closing of the offering. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell its products; the expected benefits and efficacy of the Company's products; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
Released July 10, 2018